- Home
- DCI vs JAZZ Comparison
DCI vs JAZZ Comparison
Compare DCI & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCI
- JAZZ
- Stock Information
- Founded
- DCI 1915
- JAZZ 2003
- Country
- DCI United States
- JAZZ Ireland
- Employees
- DCI N/A
- JAZZ N/A
- Industry
- DCI Pollution Control Equipment
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- DCI Industrials
- JAZZ Health Care
- Exchange
- DCI Nasdaq
- JAZZ Nasdaq
- Market Cap
- DCI 7.9B
- JAZZ 7.1B
- IPO Year
- DCI 1987
- JAZZ 2007
- Fundamental
- Price
- DCI $73.40
- JAZZ $117.77
- Analyst Decision
- DCI Hold
- JAZZ Strong Buy
- Analyst Count
- DCI 3
- JAZZ 12
- Target Price
- DCI $70.00
- JAZZ $182.75
- AVG Volume (30 Days)
- DCI 484.7K
- JAZZ 805.1K
- Earning Date
- DCI 08-27-2025
- JAZZ 08-05-2025
- Dividend Yield
- DCI 1.64%
- JAZZ N/A
- EPS Growth
- DCI N/A
- JAZZ N/A
- EPS
- DCI 2.99
- JAZZ N/A
- Revenue
- DCI $3,645,600,000.00
- JAZZ $4,086,695,000.00
- Revenue This Year
- DCI $3.14
- JAZZ $6.10
- Revenue Next Year
- DCI $3.54
- JAZZ $5.07
- P/E Ratio
- DCI $24.53
- JAZZ N/A
- Revenue Growth
- DCI 3.26
- JAZZ 4.52
- 52 Week Low
- DCI $57.45
- JAZZ $95.49
- 52 Week High
- DCI $78.95
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- DCI 57.57
- JAZZ 58.29
- Support Level
- DCI $71.79
- JAZZ $105.00
- Resistance Level
- DCI $75.81
- JAZZ $117.21
- Average True Range (ATR)
- DCI 1.09
- JAZZ 3.36
- MACD
- DCI 0.18
- JAZZ 0.20
- Stochastic Oscillator
- DCI 57.18
- JAZZ 96.96
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.6 billion in revenue and $544 million in operating income in its fiscal 2024.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.